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Objectives This study sought to evaluate the potential utility of a novel polyethylene terephthalate micronet mesh–covered
stent (MGuard) in patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing percutane-
ous coronary intervention (PCI).
Background Suboptimal myocardial reperfusion after PCI in STEMI is common and results in increased infarct size and mor-
tality. The MGuard is a novel thin-strut metal stent with a polyethylene terephthalate micronet covering designed
to trap and exclude thrombus and friable atheromatous debris to prevent distal embolization.
Methods A total of 433 patients with STEMI presenting within 12 h of symptom onset undergoing PCI were randomized at
50 sites in 9 countries to the MGuard (n  217) or commercially available bare metal or drug-eluting stents
(n  216). The primary endpoint was the rate of complete (70%) ST-segment resolution measured 60 to 90
min post-procedure.
Results Baseline characteristics were well matched between the groups. The primary endpoint of post-procedure com-
plete ST-segment resolution was significantly improved in patients randomized to the MGuard stent compared
with control patients (57.8% vs. 44.7%; difference: 13.2%; 95% confidence interval: 3.1% to 23.3%; p  0.008).
By core laboratory analysis, the MGuard stent compared with control stents also resulted in superior rates of
Thrombolysis In Myocardial Infarction 3 flow (91.7% vs. 82.9%, p  0.006) with comparable rates of myocardial
blush grade 2 or 3 (83.9% vs. 84.7%, p  0.81). Mortality (0% vs. 1.9%, p  0.06) and major adverse cardiac
events (1.8% vs. 2.3%, p  0.75) at 30 days were not significantly different between patients randomized to the
MGuard stent and control stent, respectively.
Conclusions Among patients with acute STEMI undergoing emergent PCI, the MGuard micronet mesh–covered stent com-
pared with conventional metal stents resulted in superior rates of epicardial coronary flow and complete ST-
segment resolution. A larger randomized trial is warranted to determine whether these benefits result in reduced
infarct size and/or improved clinical outcomes. (Safety and Efficacy Study of MGuard Stent After a Heart Attack
[MASTER]; NCT01368471) (J Am Coll Cardiol 2012;60:1975–84) © 2012 by the American College of Cardiol-
ogy Foundation
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MGuard in STEMI November 6, 2012:1975–84Emergent percutaneous coronary
intervention (PCI) is the optimal
reperfusion modality in patients
with acute ST-segment elevation
myocardial infarction (STEMI)
and has contributed to improved
survival in patients with cardio-
vascular disease (1,2). However,
although PCI frequently restores
normal epicardial coronary flow in
patients with STEMI, myocardial
perfusion is often suboptimal,
which results in increased infarct
size and mortality (3–5). Although
numerous mechanisms may un-
derlie the etiology of microcircula-
tory dysfunction in STEMI,
PCI-induced distal embolization
of thrombus and/or friable ather-
omatous debris is believed to be
ubiquitous and has been shown
to contribute to impaired myo-
cardial perfusion and adverse
clinical outcomes (6 – 8). To
date, efforts to improve myocar-
dial reperfusion success after PCI
in STEMI with a variety of
thrombectomy and embolic pro-
tection devices and intracoronary
administration of glycoprotein IIb/IIIa inhibitors have
yielded conflicting results (9–12). Moreover, although a
small randomized trial suggested that myocardial salvage
after failed thrombolytic therapy might be improved with
stenting compared with balloon angioplasty (13), in large
trials, the routine implantation of metal stents during
primary PCI has not been shown to enhance epicardial or
myocardial reperfusion, decrease distal embolization, or
improve left ventricular function (14–16).
The MGuard (InspireMD, Tel Aviv, Israel) is a novel
bare-metal stent (BMS) with a polyethylene terephthalate
(PET) micronet mesh covering designed to trap and exclude
embolism-prone material before distal embolization (17).
Case reports in patients with STEMI undergoing primary
PCI have demonstrated the capability of the MGuard stent
to capture thrombus and atheroma behind its net, thereby
preventing embolization (18). Use of the MGuard in
thrombotic lesions in native coronary arteries and saphenous
vein grafts (SVGs) has been reported in 4 uncontrolled
single- and multicenter studies, each demonstrating high
fees from St. Jude Medical. All other authors have reported that they have no
relationships relevant to the contents of this paper to disclose. A complete list of the
study organization and participating sites and investigators from the MASTER
(Safety and Efficacy Study of MGuard Stent After a Heart Attack) trial is provided
in the Online Appendix.
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CMRI  cardiac magnetic
resonance imaging
DES  drug-eluting stent(s)
ECG  electrocardiogram
IPTE  intraprocedural
thrombotic event
MVO  microvascular
obstruction
PCI  percutaneous
coronary intervention
PET  polyethylene
terephthalate
STEMI  ST-segment
elevation myocardial
infarction
STR  ST-segment
resolution
SVG  saphenous vein
graft
TIMI  Thrombolysis In
Myocardial Infarction
TLR  target lesion
revascularization
TVR  target vessel
revascularizationc
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012, accepted September 11, 2012.rates of procedural success with low rates of distal emboli-
zation (19–22). We therefore performed a prospective,
multicenter, randomized, controlled trial to evaluate
whether the MGuard stent improves myocardial reperfusion
in patients with STEMI undergoing PCI.
Methods
Patients. Patients 18 years of age and older presenting with
symptoms consistent with STEMI lasting 12 h in dura-
tion, with 2 mm of ST-segment elevation in 2 contig-
uous leads, intended for PCI were eligible for enrollment.
The principal clinical exclusion criteria were left bundle
branch block, paced rhythm, or other electrocardiographic
abnormality interfering with assessment of ST-segment
resolution (STR); PCI performed within 6 months or
previous coronary artery bypass graft surgery at anytime;
bleeding diathesis or indication for long-term warfarin
anticoagulation; allergy or contraindication to antiplatelet
agents, anticoagulant therapy, metal stent or mesh material,
and/or iodinated contrast that cannot be adequately pre-
medicated; known renal insufficiency (serum creatinine
2.0 mg/dl) or on dialysis; left ventricular ejection fraction
20%, cardiogenic shock, or cardiopulmonary resuscitation;
and comorbid conditions that may cause noncompliance
with the protocol or are associated with a life expectancy1
year.
Angiographic eligibility required planned PCI of a single
de novo lesion 33 mm in length and reference vessel
diameter (RVD) 3.0 to 4.0 mm by visual estimation,
apable of being covered by a single study stent. Patients
ere not eligible if a 50% left main stenosis was present;
f the target lesion was ostial in location or involved a
ifurcation with a 2.0-mm side branch; if the target vessel
r lesion was excessively tortuous or angulated or had
oderate to heavy calcification; if a50% stenosis proximal
r distal to the target lesion was present; or if any previous
tent was identified proximal to or within 10 mm distal to
he target lesion. In the case of an occluded infarct vessel,
ngiographic eligibility was assessed only after restoration of
hrombolysis In Myocardial Infarction (TIMI) flow grade
2 by a guidewire, manual aspiration, or balloon angio-
lasty.
tudy design and protocol procedures. The protocol was
pproved by the ethics committee at each participating center,
nd informed written consent was obtained in all clinically
ligible patients. Before cardiac catheterization, consented
atients were administered aspirin 300 to 325 mg chewed or
50 to 500 mg intravenously and either 600 mg clopidogrel,
0 mg prasugrel, or 180 mg ticagrelor. Emergent left
entriculography and 3-vessel coronary arteriography were
hen performed. If all angiographic eligibility criteria were
et, the patient was then randomized 1:1 to either the
Guard stent or, per operator discretion, any commercially
vailable BMS or drug-eluting stent (DES), the latter
ollectively comprising the control group (as differences in
a
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November 6, 2012:1975–84 MGuard in STEMIthe acute rates of TIMI flow, myocardial blush grade or
STR have not been reported as a function of stent type)
(22). Randomization in alternating block sizes of 6 was
performed by opening sealed envelopes, stratified by infarct
vessel (left anterior descending vs. other) and the intended
use versus nonuse of thrombus aspiration (per operator
discretion).
Procedural anticoagulation consisted of unfractionated
heparin plus intravenous glycoprotein IIb/IIIa inhibition or
bivalirudin monotherapy. Procedural use of low molecular
weight heparin, fondaparinux, and intracoronary glyco-
protein IIb/IIIa inhibition was not permitted. The decision
to perform manual thrombus aspiration and/or pre-dilate
before stenting was left to operator discretion, but if
required, a 1.5- or 2.0-mm balloon diameter was suggested
to minimize the risk of embolization before stenting. Larger
balloons could be used if stent passage was unsuccessful.
Rheolytic thrombectomy was not permitted other than for
major procedural complications. The need for further bal-
loon dilation after stent implantation was left to operator
discretion, with the goal of achieving as close to a 0% visual
residual stenosis as possible. Only the single culprit lesion
was treated during the index procedure; staged PCI in a
noninfarct vessel was permitted 72 h post-procedure.
A 12-lead electrocardiogram (ECG) was obtained 60 to 90
min post-procedure. All patients were treated with aspirin (75
to 162 mg/day) indefinitely and an adenosine diphosphate
receptor antagonist for 1 year. High-dose statins, beta-
blockers, and angiotensin-converting enzyme inhibitors or
receptor blockers were also prescribed in the absence of
contraindications. Clinical follow-up was performed at 30
days, 6 months, and 12 months. To assess late vascular
responses, angiographic follow-up at 13 months was per-
formed in 50 consecutive MGuard patients at 17 partici-
pating centers. A subset of 60 consecutive randomized
patients at 7 participating centers also underwent cardiac
magnetic resonance imaging (CMRI) at 3 to 5 days post-
PCI for assessment of infarct size and microvascular ob-
struction (MVO). The present study is reported after
completion of the 30-day follow-up period in all patients.
The local principal investigator and research coordinators
were aware of the study assignments. The patients, core
laboratory technicians, clinical event adjudication commit-
tee, executive committee, and sponsor were blinded to the
randomized treatment. Independent study monitors re-
viewed all source documents on-site for accuracy and
completeness.
Device description. The MGuard consists of a balloon-
expandable BMS platform with a PET micronet sleeve
coating (fiber width, 20 m; aperture size, 150 180 m)
ttached to its outer surface (Fig. 1) (17–22). The micronet
oles are expandable, so side branches may still be accessed
hrough the mesh. The first-generation stent had a 316L
tainless steel frame (strut thickness, 100 m), whereas the
current MGuard Prime platform is composed of cobalt
chromium (strut thickness, 80 m). The micronet mesh isthe same in both stents, although the range of available
diameters and lengths varies slightly. The MGuard Prime
stent became available late during the study recruitment
period.
Endpoints and definitions. The primary endpoint was
the rate of complete STR, defined as 70% reduction in
the summed 12-lead extent of ST-segment elevation
from the baseline to the post-procedure ECG, as deter-
mined by a blinded, independent electrocardiographic
core laboratory. As a secondary analysis, the rate of STR was
also determined in the lead with the greatest baseline degree
of ST-segment elevation. The statistical analysis plan pre-
specified that the primary analysis population would consist
of all patents with at least 1 mm of baseline ST-segment
elevation in at least 2 contiguous leads (as assessed by the
core laboratory) with a qualifying paired ECG obtained
within 120 min post-procedure. Secondary endpoints con-
sisted of acute device, lesion, and angiographic success rates,
post-procedural TIMI flow, corrected TIMI frame count,
myocardial blush grade, and intraprocedural thrombotic
events (IPTEs), defined as the development of new or
increasing thrombus, abrupt vessel closure, no reflow, slow
reflow, distal embolization, side branch closure, or intrap-
rocedural stent thrombosis at any time during the procedure
and were determined by independent angiographic core
laboratories, as previously described (23,24). Major adverse
cardiovascular and cerebral events (the composite of all-
cause death, reinfarction, stroke or ischemia-driven target
lesion revascularization [TLR]), major adverse cardiovascu-
lar events (the composite of cardiac death, reinfarction, or
Figure 1 The MGuard Stent
The MGuard stent has a 316L stainless steel frame with 100-m strut thick-
ness. It is manufactured in diameters ranging from 2.0 to 4.0 mm and in
lengths ranging from 11 to 39 mm. The crossing profile ranges from 1.0 to 1.3
mm. The MGuard Prime stent is similar in configuration, but has a L605 cobalt
chromium alloy frame with 80-m strut thickness and slightly lower crossing
profile. It is manufactured in diameters ranging from 2.5 to 4.0 mm and in
lengths ranging from 13 to 38 mm. The polyethylene terephthalate micronet is
identical on both stents and has a fiber width of 20 m and an expanded aper-
ture size of 150  180 m. Both stents are compatible with 0.014-inch guide-
wires and 6-French guiding catheters.ischemia-driven TLR); stroke, stent thrombosis (Academic
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MGuard in STEMI November 6, 2012:1975–84Research Consortium definition), and major bleeding
(TIMI definition) were adjudicated by an independent
clinical events committee blinded to treatment assignment.
Absolute and relative (percentage of total left ventricular
mass) infarct size and MVO at 3 to 5 days post-procedure
were determined at an independent CMRI core laboratory
using previously described methodology (12).
Power and statistical analysis. With 412 assessable pa-
tients, the trial had 80% power to demonstrate a 21.7%
relative improvement in the frequency of complete STR
from 60% to 73% with a 2-sided  0.05. Assuming a 95%
rate of assessable paired ECGs, enrollment was planned for
432 patients.
All analyses were performed by intention to treat. Miss-
ing data were not replaced. Categorical outcomes were
compared by the chi-square or Fisher exact test. Continuous
variables are presented as median with interquartile range
and were compared by the Wilcoxon rank sum test. All
statistical tests were 2 sided. A p value 0.05 was
considered significant for all analyses. Subgroup analysis
with interaction testing by logistic regression was pre-
specified to examine the consistency of treatment effect
for the primary endpoint, according to age, sex, diabetes,
infarct artery, baseline TIMI flow, and time from symp-
tom onset to PCI. All statistical analyses were performed
using SAS version 9.2 (SAS Institute Inc., Cary, North
Baseline Characteristics of the Randomized GroTable 1 Baseline Characteristics of the Ran
Age, yrs
Male
Hypertension
Hyperlipidemia
Diabetes mellitus
Current cigarette smoking
Previous myocardial infarction
Previous percutaneous coronary intervention
Body mass index, kg/m2
Symptom to hospital arrival, min
Hospital arrival to first device, min
Symptom onset to first device, min
Infarct artery lesion location*
Left anterior descending coronary artery
Left circumflex coronary artery
Right coronary artery
Baseline TIMI flow grade*
0/1
2
3
Baseline reference vessel diameter, mm*
Baseline minimal luminal diameter, mm*
Baseline diameter stenosis, %*
Values are median (interquartile range) or n (%). *Assessed by core la
TIMI  Thrombolysis In Myocardial Infarction.Carolina). wResults
Patients and procedures. Between July 22, 2011 and May
29, 2012, 433 patients with STEMI were enrolled and
randomized at 50 sites in 9 countries to the MGuard stent
(n 217) or a control stent (n  216). Baseline clinical and
ngiographic features were well matched between the 2
roups (Tables 1 and 2). The median age was 59 years, and
4% of patients were female. The infarct vessel was the left
nterior descending coronary artery in 40.2% of patients, the
ight coronary artery in 51.3%, and the left circumflex
oronary artery in 8.3%; a single lesion was treated in all
atients. Aspiration was performed in approximately two
hirds of patients in each group, and pre-dilation before
tent implantation was performed in50% of patients, with
median 2.0-mm diameter balloon. Use of antiplatelet
gents, anticoagulants, and other study procedures were also
imilar between the 2 groups.
evice performance. The MGuard stent was unable to
each or cross the lesion in 9 of 217 patients (4.1%),
ncluding 9 of 191 (4.7%) and 0 of 26 (0%) patients in
hom the original MGuard and MGuard Prime devices
ere used, respectively. There were 2 cases of MGuard stent
islodgment, both occurring during attempted withdrawal
f the device after unsuccessful vessel passage. In 1 patient,
he stent embolized peripherally without clinical sequelae;
alloon angioplasty of the infarct lesion was performed
zed Groups
MGuard Stent
(n  217)
Control Stent
(n  216)
0.0 (52.0–68.0) 58.0 (51.0–67.0)
63 (75.1) 166 (76.9)
15 (42.3) 100/211 (47.4)
12 (27.4) 57/210 (27.1)
26 (12.0) 39 (18.1)
20 (55.3) 101 (46.8)
8 (3.7) 19 (8.8)
8 (3.7) 12 (5.6)
6.6 (24.5–30.2) 26.7 (24.8–30.2)
0.5 (95.5–246.0) 175.0 (92.0–320.0)
5.0 (33.0–72.0) 45.0 (31.5–72.0)
6.5 (155.5–307.5) 240.0 (140.0–383.0)
87 (40.1) 87 (40.3)
20 (9.2) 17 (7.9)
10 (50.7) 112 (51.9)
15 (66.5) 159/215 (74.0)
15 (18.1) 29/215 (13.5)
15 (15.3) 27/215 (12.6)
.15 (2.87–3.38) 3.06 (2.87–3.40)
.00 (0.00–0.45) 0.00 (0.00–0.34)
0.0 (85.2–100.0) 100.0 (88.3–100.0)
ry quantitative coronary angiography.upsdomi
6
1
91/2
58/2
1
2
15
4
20
1
143/2
39/2
33/2
3
0
10ithout stent implantation. In the second case, the stent
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November 6, 2012:1975–84 MGuard in STEMIdislodged in the proximal vessel where it was implanted.
The infarct lesion in the distal vessel was then crossed and
successfully treated with a commercially available BMS.
There were no device failures in the control group.
Angiographic measures. As seen in Table 3, device success
was lower with the MGuard stent compared with the
control stents, although lesion success was similar. TIMI-3
flow was restored more frequently in patients randomized to
the MGuard stent compared with the control stents, how-
ever, and as a result, angiographic success rates were higher
in the MGuard group (91.7% vs. 82.4%, p  0.004). There
were no statistically significant post-PCI differences be-
tween the stent groups in corrected TIMI frame count,
myocardial blush grade, or the occurrence of IPTE.
Primary endpoint: ST-segment resolution. Qualifying
baseline and post-procedure ECGs were available for 412
and 410 of the 433 randomized patients (95.2% and 94.7%,
respectively). As shown in Table 4, the primary endpoint of
omplete STR summed across the 12-lead ECG was
chieved in a significantly greater percentage of patients
Procedural Details and MedicationsTable 2 Procedural Details and Medications
MGuard
(n  2
Antiplatelet agents, periprocedural
Aspirin 214 (98
ADP antagonists 207 (95
Clopidogrel 151/207 (72
Ticlopidine 1/207 (0.
Prasugrel 45/207 (21
Ticagrelor 10/207 (4.
Anticoagulation, periprocedural
Unfractionated heparin 210 (96
Glycoprotein IIb/IIIa inhibitor 180 (82
Bivalirudin 24 (11
Aspiration performed 143 (65
Balloon pre-dilation performed 109 (50
Direct stenting 26 (12
1 stent implanted 216 (99
2 stents implanted 28 (12
Stent type
MGuard 208/216 (96
Bare-metal stent 3/216 (1.
Drug-eluting stent 5/216 (2.
Total stent length, mm 19.0 (15
Post-stent dilation performed 79 (36
Maximal device size, mm 3.5 (3.
Maximal dilation pressure, atm 16 (14
Discharge medications
Aspirin 217 (10
ADP antagonists 217 (10
Beta-blockers 194 (89
ACE inhibitors 189 (87
Angiotensin-receptor blockers 16 (7.
Statins 214 (98
Values are n (%), n/N (%), or median (interquartile range). *Marginall
ACE  angiotensin-converting enzyme; ADP  adenosine diphosphandomized to the MGuard stent than to the control stents s(57.8% vs. 44.7%; difference, 13.2%; 95% confidence inter-
val: 3.1 to 23.3; p  0.008). The secondary endpoint of
complete STR in the lead with the greatest ST-segment
elevation was also greater with the MGuard stent. The
greater rate of complete STR with the MGuard stent
compared with the control stents was consistent across
numerous subgroups (Fig. 2).
Clinical outcomes and cardiac magnetic resonance imaging.
Clinical follow-up at 30 days was complete in 431 of 433
patients (99.5%); follow-up was not available for 2 control
patients. Adverse clinical events were infrequent in both
groups at 30 days (Table 5). Pooled across stent type,
mortality at 30 days occurred in 0 of 211 patients with
complete (70%) STR and in 4 of 198 patients with partial
or absent (70%) STR (0% vs. 2.0%, p  0.05), and a
nonsignificant trend toward lower mortality was present in
the MGuard arm (0% vs. 1.9%, p 0.06). Reinfarction and
tent thrombosis each occurred in 3 MGuard patients and 2
ontrol stent patients (1.4% vs. 0.9%, p  1.0). Ischemia-
riven TVR occurred in 6 MGuard patients and 1 control
Control Stent
(n  216) p Value
214 (99.1) 1.0
207 (95.8) 0.82
145/207 (70.0) 0.51
0/207 (0.0) 1.0
43/207 (20.8) 0.81
19/207 (9.2) 0.08
208 (96.3) 0.79
180 (83.3) 0.92
27 (12.5) 0.64
145 (67.1) 0.79
97 (44.9) 0.27
23 (10.6) 0.66
216 (100.0) 1.0
23 (10.6) 0.47
1 (0.5) 0.0001
129 (59.7) 0.0001
86 (39.8) 0.0001
.0) 20.0 (15.0–24.0) 0.64
66 (30.6) 0.20
3.5 (3.0–.5) 0.78
16 (14–18) 0.02*
214/215 (99.5) 0.50
214/215 (99.5) 0.50
197/215 (91.6) 0.43
182/215 (84.7) 0.47
15/215 (7.0) 0.87
208/215 (96.7) 0.22
r in the MGuard group.Stent
17)
.6)
.4)
.9)
5)
.7)
8)
.8)
.9)
.1)
.9)
.2)
.0)
.5)
.9)
.3)
4)
3)
.0–24
.4)
0–3.5)
–18)
0.0)
0.0)
.4)
.1)
4)
.6)tent patient (2.8% vs. 0.5%, p  0.12). Among 59 patients
yocard
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MGuard in STEMI November 6, 2012:1975–84in whom CMRI was completed, there were no significant
differences in infarct size or MVO between the 2 groups
(Table 6).
Discussion
In the present prospective, multicenter, single-blind, ran-
domized, controlled trial, the MGuard PET micronet
mesh–covered stent compared with the use of standard
metal stents in patients with acute STEMI undergoing
Angiographic Measures Post-PCITable 3 Angiographic Measures Post-PCI
MGuard
(n  2
Device success* 208 (95.
Lesion success† 217 (100
Angiographic success‡ 199 (91.
Reference vessel diameter, mm§ 3.20 (2.9
Minimal luminal diameter, mm§
In-stent 2.99 (2.7
In-lesion 2.64 (2.4
Diameter stenosis, %§
In-stent 6.9 (4.2
In-lesion 15.3 (9.6
TIMI flow grade§
0/1 4 (1.8
2 14 (6.5
3 199 (91.
Corrected TIMI frame count§ 17.0 (12.
Myocardial blush grade§
0/1 35 (16.
2 21 (9.7
3 161 (74.
2/3 182 (83.
IPTE§ 47 (21.
Values are n (%) or median (interquartile range). *Device success  a
randomized stent. †Lesion success  attainment of 50% final
‡Angiographic success  attainment of 50% final residual stenosis
quantitative coronary angiography.
IPTE  intraprocedural thrombotic event; TIMI  Thrombolysis In M
Core Laboratory Electrocardiographic ResultsTable 4 Core Laboratory Electrocardiograph
Baseline ECG, total ST-segment elevation, mm
Baseline ECG, worst lead ST-segment elevation, mm
Post-procedure to second ECG, min
ST-segment resolution, sum of all leads
Complete (70%)
Partial (30% to 70%)
Absent (30%)
Median (IQR), % (range)
ST-segment resolution, worst lead
Complete (70%)
Partial (30% to 70%)
Absent (30%)
Median (IQR), %
Values are median (interquartile range) or n (%). *Two control patient
1 patient left bundle branch block developed, whereas in the second patient
ECG  electrocardiogram; IQR  interquartile range.emergent PCI resulted in significantly higher rates of TIMI
flow grade 3, acute angiographic success, and complete
STR, the latter representing the powered primary endpoint
of the study. The greater rate of complete STR achieved
with the MGuard stent was consistent among numerous
important subgroups, including infarct vessel, lesion length,
reference vessel diameter, and use of aspiration. In previous
STEMI studies, restoration of TIMI-3 flow and complete
STR after PCI have been strongly associated with subse-
Control Stent
(n  216) p Value
214 (99.1) 0.03
215 (99.5) 0.50
178 (82.4) 0.004
) 3.16 (2.91–3.46) 0.99
) 2.99 (2.69–3.31) 0.91
) 2.64 (2.36–2.95) 0.82
6.4 (3.9–10.3) 0.56
15.4 (10.8–21.2) 0.66
12 (5.6) 0.01
25 (11.6) 0.06
179 (82.9) 0.006
) 18.0 (13.0–22.0) 0.23
32 (14.8) 0.71
28/215 (13.0) 0.27
155/215 (72.1) 0.62
183 (84.7) 0.81
48/215 (22.3) 0.87
nt of 50% final residual stenosis of the target lesion using only the
l stenosis of the target lesion using any percutaneous method.
arget lesion and final TIMI flow grade 3. §Assessed by core laboratory
ial Infarction.
sults
Guard Stent
(n  204)
Control Stent
(n  208) p Value
0 (6.55–15.00) 9.65 (6.15–15.00) 0.64
5 (2.20–5.00) 3.20 (2.20–4.50) 0.74
5 (63.5–81.0) 72.0 (63.0–80.0) 0.71
n  204 n  206*
8 (57.8) 92 (44.7) 0.008
2 (25.5) 79 (38.3) 0.005
4 (16.7) 35 (17.0) 0.95
4 (45.3–90.8) 64.5 (39.3–88.6) 0.07
6 (66.7) 118 (57.3) 0.05
4 (21.6) 64 (31.1) 0.03
4 (11.8) 24 (11.7) 0.97
8 (62.5–100.0) 76.2 (50.0–100.0) 0.01
ualifying baseline ECGs did not have interpretable follow-up ECGs; inStent
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November 6, 2012:1975–84 MGuard in STEMIquent early and late survival (25–27). Concordantly, mor-
tality at 30 days in the present trial was significantly greater
in patients not achieving complete STR, resulting in a
strong trend toward reduced cardiac and all-cause mortality
in patients treated with the MGuard stent compared with a
Figure 2 Subgroup Analysis for the Primary Endpoint of Comple
Subgroup analysis comparing patients randomized to the MGuard stent versus a c
the relative risk between groups (black boxes) with 95% confidence intervals (CI)
for interaction between the variable and the relative treatment effect. CMRI  card
anterior descending; MBG  myocardial blush grade; MVO  microvascular obstru
ence vessel diameter; STR  ST-segment resolution; SVG  saphenous vein graftcontrol stent.Although not directly evaluated in the present study, the
higher rate of reperfusion success with the MGuard stent is
likely due to its design, affording trapping and exclusion of
thrombus and friable atheromatous debris before emboliza-
tion to the distal microvasculature (17,18). Consistent with
-Segment Resolution
stent for the primary endpoint of complete ST-segment resolution, displayed as
ntal limit lines). The probability for interaction [P(Int)] represents the likelihood
agnetic resonance imaging; IPTE  intraprocedural thrombotic events; LAD  left
PET  polyethylene terephthalate; PTFE  polytetrafluoroethylene; RVD  refer-
 Thrombolysis In Myocardial Infarction.te ST
ontrol
(horizo
iac m
ction;
; TIMIthis hypothesis, although the exploratory CMRI study was
t1982 Stone et al. JACC Vol. 60, No. 19, 2012
MGuard in STEMI November 6, 2012:1975–84underpowered to demonstrate significant intergroup differ-
ences, the numerically lower rates of MVO seen in the
MGuard stent group suggests that early microcirculatory
function may be improved compared with a control stent
(28,29). Similarly, infarct size was numerically smaller and
global wall motion and left ventricular ejection fraction were
directionally improved at 3 to 5 days post-PCI, although
these results should be interpreted cautiously given the
modest substudy size. Conversely, no differences between
the stent types were seen in the rates of myocardial blush,
macroemboli, or IPTE, indices that have also been corre-
lated with outcomes after PCI in STEMI and acute coronary
syndromes (8,23,24). Although it is possible that these mea-
sures are less sensitive or prognostic than STR (or assess
different mechanisms of reperfusion success), a larger random-
Clinical Events at 30-Day Follow-UpTable 5 Clinical Events at 30-Day Follow-Up
MGuard Stent
(n  217)
Control Stent
(n  214) p Value
MACCE 5 (2.3) 5 (2.3) 1.00
MACE 4 (1.8) 5 (2.3) 0.75
All-cause mortality 0 (0.0) 4 (1.9)* 0.06
Reinfarction 3 (1.4) 2 (0.9) 1.00
Q-wave 3 (1.4) 1 (0.5) 0.62
Non–Q-wave 0 (0.0) 1 (0.5) 0.50
TLR, ischemia-driven 4 (1.8) 1 (0.5) 0.37
TVR, ischemia-driven 6 (2.8) 1 (0.5) 0.12
Stent thrombosis, definite or
probable
3 (1.4) 2 (0.9) 1.00
Acute (24 h) 1 (0.5) 0 (0.0) 1.00
Subacute (24 h–30 days) 2 (0.9) 2 (0.9) 1.00
Definite 3 (1.4) 1 (0.5) 0.62
Acute (24 h) 1 (0.5) 0 (0.0) 1.00
Subacute (24 h–30 days) 2 (0.9) 1 (0.5) 1.00
Probable 0 (0.0) 1 (0.5) 0.50
Acute (24 h) 0 (0.0) 0 (0.0) —
Subacute (24 h–30 days) 0 (0.0) 1 (0.5) 0.50
Stroke 1 (0.5) 0 (0.0) 1.00
TIMI bleeding 4 (1.8) 4 (1.9) 1.00
Major 3 (1.4) 2 (0.9) 1.00
Minor 1 (0.5) 2 (0.9) 0.62
Values are n (%). *All deaths were cardiac.
MACCE  major adverse cardiovascular or cerebral events; MACE  major adverse cardiac
events; TIMI Thrombolysis In Myocardial Infarction; TLR target lesion revascularization; TVR
arget vessel revascularization.
Cardiac Magnetic Resonance Imaging SubstudyTable 6 Cardiac Magnetic Resonance Imag
Total LV myocardial mass, g 1
Infarct mass, g 1
Infarct mass, % of total LV mass 1
Total microvascular obstruction, g
Microvascular obstruction, % of total LV mass
Total abnormal wall motion score 2
LV ejection fraction, % 4Values are median (interquartile range).
LV  left ventricular.ized trial is warranted to definitively demonstrate whether the
MGuard stent reduces infarct size and/or improves clinical
outcomes compared with standard metal stents.
Stent grafts were unsuccessful in previous studies in
preventing distal embolization during PCI of diseased
SVGs and were associated with high rates of restenosis and
reocclusion (30–33). However, these devices were covered
with a single or dual layer of tightly woven polytetrafluoro-
ethylene and were thus incapable of trapping friable material
without extruding it downstream (“toothpaste” effect). In
contrast, the MGuard stent is constructed with a loosely
interlaced PET micronet mesh that by optical coherence
tomography has been shown to trap and exclude thrombus
before distal embolization (18). Thus, the results with these
2 devices would be expected to be quite different. Moreover,
PCI in STEMI (as tested in the present trial) and SVGs are
not comparable, although preliminary results with the
MGuard stent in SVGs have been favorable (19,20).
The MGuard stent was unable to reach or cross the
infarct lesion in 9 of 217 patients (4.1%). Stent embolization
occurred in 2 of these patients, without adverse clinical
sequelae. The MGuard stent has a higher profile and is less
flexible than a standard stent, and retention of the current
device may not be as robust. Manual thrombus aspiration
and/or pre-dilation with a small balloon angioplasty cathe-
ter were performed in most patients in the current study.
Lesion pre-dilation with a balloon sized 1:1 to the reference
vessel before MGuard stent passage may improve device
deliverability, but may also reduce the extent to which
embolization can be prevented. Of note, there were no
device failures in the present study among the 26 patients in
whom the lower profile and more flexible MGuard Prime
device was used, and additional device iterations are under
way to further improve acute performance.
Long-term follow-up is ongoing at the time of this report
and is essential to examine the late results with the MGuard
stent after primary PCI in STEMI. In the largest study
before the MASTER (Safety and Efficacy Study of
MGuard Stent After a Heart Attack) trial, none of 60
patients required ischemia-driven TLR within 6 months
after MGuard stent implantation in STEMI (21). This
small study notwithstanding, as the MGuard stent lacks an
ults at Days 3 to 5ubstudy Results at Days 3 to 5
d Stent
30)
Control Stent
(n  29) p Value
7–163) 147 (118–174) 0.41
.0–30.0) 22.3 (15.7–30.1) 0.27
9–25.0) 16.6 (10.0–22.6) 0.48
0–1.6) 1.0 (0.2–2.8) 0.14
0–1.4) 0.8 (0.2–1.9) 0.39
.0–26.0) 25.0 (21.0–27.0) 0.48
.5–52.3) 47.3 (42.0–54.5) 0.79Resing S
MGuar
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41 (11
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November 6, 2012:1975–84 MGuard in STEMIantiproliferative agent, it is not expected to match a DES in
protection from restenosis. However, the absolute clinical
benefit of DES compared with BMS in preventing
ischemia-driven TLR in STEMI is modest (34) and must
be weighed against the potential utility of the MGuard stent
in reducing infarct size, heart failure events, and mortality.
Both BMS and DES are currently used in a substantial
proportion of patients undergoing primary PCI in STEMI,
with DES use reserved at most centers for lesions at high
risk of restenosis. However, these longer and more complex
lesions may possess greater potential for embolization and
thus theoretically may benefit most by use of the MGuard
stent. Moreover, stent thrombosis is common in STEMI
with both BMS and DES (35,36), and although no signif-
icant differences in the rates of thrombotic events between
the MGuard and conventional stents at 30 days were
observed, the present study was underpowered in this
regard. These considerations reinforce the need for a larger
randomized trial comparing the MGuard stent with both
BMS and DES across the range of lesions encountered
among patients with STEMI, with long-term follow-up to
fully characterize the competing risks and benefits of these
devices.
Study limitations. The MASTER trial was underpowered
to draw definitive conclusions regarding infarct size and
clinical events, and all subgroup analyses should be consid-
ered hypothesis-generating. Longer-term clinical and an-
giographic follow-up is ongoing to characterize the late
vascular responses of the MGuard stent. More experience
with the MGuard Prime device in STEMI is required. The
discordance in findings between TIMI flow, STR, blush,
and IPTE has been noted. Finally, although events were
assessed and adjudicated by independent blinded core labora-
tories and clinical events committees, the operators and re-
search coordinators were not blinded to stent assignment, and
thus some degree of bias cannot be excluded. The directional
concordance of most of the outcome measures, including
TIMI flows and frame counts, STR, MVO, infarct size, and
mortality provides consistency and validity to the results.
Conclusions
Among patients with acute STEMI undergoing emergent
PCI enrolled in the present multicenter, randomized, con-
trolled trial, the MGuard micronet mesh–covered stent
compared with conventional metal stents resulted in supe-
rior rates of epicardial coronary flow and complete STR.
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APPENDIX
For a complete list of the study organization and participating sites and
investigators from the MASTER trial, please see the online version of this
article.
